Research and Markets has announced the addition of the "Uterine Cancer - Pipeline Insights, 2017" report to their offering.
Uterine Cancer - Pipeline Insights, 2017 provides in depth insights on the pipeline drugs and their development activities around the Uterine Cancer.
This report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.
Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.
This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Uterine Cancer.
This report also assesses the Uterine Cancer therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.
Key Topics Covered:
- Uterine Cancer Overview
- Uterine Cancer Pipeline Therapeutics
- Uterine Cancer Therapeutics under Development by Companies
- Uterine Cancer Filed and Phase III Products
- Comparative Analysis
- Uterine Cancer Phase II Products
- Comparative Analysis
- Uterine Cancer Phase I and IND Filed Products
- Comparative Analysis
- Uterine Cancer Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Uterine Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Uterine Cancer - Discontinued Products
- Uterine Cancer - Dormant Products
- Companies Involved in Therapeutics Development for Uterine Cancer
- Appendix
For more information about this report visit http://www.researchandmarkets.com/research/gvwfmx/uterine_cancer
View source version on businesswire.com: http://www.businesswire.com/news/home/20170126005473/en/